Cridanimod |
| رقم الكتالوجGC38648 |
Cridanimod هو منشط قوي لمستقبلات البروجسترون (PR) من خلال تحريض تعبير IFNα و IFNβ
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 38609-97-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Cridanimod is a small-molecule immunomodulator and interferon inducer[1]. Cridanimod is a potent progesterone receptor (PR) activator mediated through induction of IFNα and IFNβ expression[2].
Cridanimod (IM; 1-6 mg; twice a week) has a significantly longer survival time. Cridanimod significant increases in IFNα and -β in cridanimod-treated mice in a dose-dependent manner[1]. Animal Model: Athymic mice with hec50co cells[1]
[1]. Xenetic Biosciences Announces FDA Acceptance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of Virexxa® in Endometrial Cancer. AUGUST 19, 2016 [2]. Matthew J. Carlson, et al. Cridanimod and progestin therapy in hormone-resistant endometrial cancer. Journal of Clinical Oncology, January 30, 2017.
Average Rating: 5 (Based on Reviews and 32 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *